Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 4/20 | 0.39 |
| ▸ | MYC | P01106 | 5/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371934 | 0.81 | CFTR (0.49) | — | |
| SCHEMBL29699221 | 0.80 | MYC (0.44) | MYCGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL2372656 | 0.80 | MYC (0.44) | MYCGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL2372056 | 0.79 | CFTR (0.45) | MYCGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL29699241 | 0.79 | CFTR (0.45) | MYCGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL2373031 | 0.77 | MYC (0.44) | MYCGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL2372906 | 0.74 | CFTR (0.44) | RBP4MYCTTRGRIA1GRIA2 | |
| SCHEMBL13518970 | 0.72 | CFTR (0.42) | RBP4MYCHSD17B10KDM4EALDH1A1 | |
| SCHEMBL2372480 | 0.72 | CFTR (0.40) | RBP4MYCGRIA1GRIA2GRIA3 | |
| SCHEMBL22775054 | 0.71 | CFTR (0.48) | RBP4MYCMAPTGRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | disclosed |
| EP-3980121-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | Novartis AG (CH) | 2022-04-13 | — | — | EP | disclosed |
| CN-113891744-A | Pyridine and pyrazine derivatives for the treatment of CF, COPD and bronchiectasis | 诺华股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| WO-2020250116-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | NOVARTIS AG (CH) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020250116-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | NOVARTIS AG (CH) | 2020-12-17 | — | — | WO | disclosed |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG | 2012-11-01 | — | — | US | disclosed |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG | 2012-11-01 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| WO-2011113894-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| WO-2011113894-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | RBP4 4098/4885MYC 3213/4885JAK3 333/4885 |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | RBP4 4098/4885MYC 3213/4885JAK3 333/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | RBP4 3971/4885MYC 2727/4885JAK3 278/4885 |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | RBP4 4263/4885MYC 2535/4885JAK3 291/4885 |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | RBP4 4098/4885MYC 3213/4885JAK3 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.